Purple Biotech Ltd. is a clinical-stage company focused on the development of first-in-class therapies aimed at overcoming tumor immune evasion and drug resistance. The company is dedicated to the oncology field and is exploring innovative treatment options to enhance patient outcomes in cancer therapy.
The company’s research and development efforts are geared toward creating unique therapeutic solutions that target the mechanisms by which tumors can evade the immune system and develop resista...
Purple Biotech Ltd. is a clinical-stage company focused on the development of first-in-class therapies aimed at overcoming tumor immune evasion and drug resistance. The company is dedicated to the oncology field and is exploring innovative treatment options to enhance patient outcomes in cancer therapy.
The company’s research and development efforts are geared toward creating unique therapeutic solutions that target the mechanisms by which tumors can evade the immune system and develop resistance to established therapies. Its pipeline includes promising candidates addressing various aspects of immune regulation and cancer progression. The company evidences a strong commitment to advancing medical science by leveraging its proprietary technologies to form the basis for novel treatment strategies.
Business Segments
The company operates primarily in the pharmaceutical and biotechnology sectors, concentrating on oncology.
The principal segments within the company's operations include,
CM24
This segment involves a humanized monoclonal antibody that specifically targets and blocks the interactions of Carcinoembryonic Antigen Related Cell Adhesion Molecule 1 (CEACAM1). CEACAM1 is recognized as an immune checkpoint protein that facilitates tumor immune evasion and survival via various pathways. By inhibiting this interaction, CM24 aims to enhance immune responses against tumors, thus potentially improving therapeutic efficacy in patients.
NT219
This segment encompasses a small molecule that strategically targets and inhibits Insulin Receptor Substrate 1 and 2 (IRS1/2) along with Signal Transducer and Activator of Transcription (STAT3). These pathways are critical in the development of resistance to cancer therapies. NT219 seeks to disrupt these signal transductions, ultimately leading to enhanced sensitivity of tumors to existing treatment regimens.
Tri-Specific Antibodies Platform
The company also boasts a platform technology that focuses on conditionally activated tri-specific antibodies capable of engaging both T cells and Natural Killer (NK) cells. This innovative approach aims to elicit a potent, localized immune response within the tumor microenvironment (TME). The company has developed a cleavable capping technology to ensure that therapeutic activity remains confined to the TME, improving the anticipated therapeutic window in patients and limiting systemic exposure.
This diversified portfolio positions the company favorably within the competitive landscape of oncology therapeutics, allowing the company to address unmet medical needs through multifaceted approaches.
Business Strategy
The company’s business strategy centers on advancing its clinical pipeline while fostering partnerships and collaborations that enhance its research capabilities and accelerate the development process. The company reallocates significant resources toward clinical trials for its lead candidates CM24 and NT219, aiming to elucidate their therapeutic potentials in addressing both immune evasion and drug resistance.
The company recognizes the significance of integrating cutting-edge scientific research, clinical insights, and patient feedback into its strategic planning. By maintaining a focus on innovative therapeutic modalities and leveraging its proprietary technologies, the company is determined to make a substantial impact in the field of oncology.
Within this framework, the company actively seeks to establish partnerships with research institutions and other biotechnology firms to augment its development efforts. Such collaborations could provide essential funding, technological resources, and access to advanced research capabilities that enhance the effectiveness of the company’s drug development process.
Essentially, the company’s strategy is underpinned by a commitment to discovery and innovation, leading to the development of transformative therapies that improve treatment outcomes for cancer patients. Long-term, the company aims to position itself as a leader in oncology, effectively contributing to the evolution of cancer therapy through its differentiated product offerings.
Products and Services
The company specializes in developing advanced therapeutic solutions for oncology. Its product pipeline includes several significant assets,
CM24
A novel humanized monoclonal antibody designed to inhibit the engagement of CEACAM1, promoting a robust immune response against tumor cells through various immunological pathways.
NT219
A small molecule targeting key signal transduction pathways implicated in cancer drug resistance. By simultaneously inhibiting IRS1/2 and STAT3, NT219 seeks to rejuvenate cancer therapies' efficacy and contribute to improved patient response rates.
Tri-Specific Antibodies
This product reflects the company's commitment to innovating immunotherapeutic strategies. These antibodies are designed to operate both T cells and NK cells, inducing localized immune responses with the potential for significantly improved therapeutic windows in cancer treatment.
The company focuses on the efficacy and safety of its products, ensuring that they meet rigorous regulatory standards while delivering the therapeutic impact necessary for patient care.
Geographical Markets Served
The company operates primarily in Israel and seeks to expand its impact on a global scale, particularly in jurisdictions known for robust pharmaceutical and biotechnology markets, such as the United States and Europe. The company has established its research and operational infrastructure in Israel, leveraging the local expertise and innovation culture to advance its clinical programs.
Customers
The company primarily targets stakeholders within the oncology sector, including healthcare providers, research institutions, and pharmaceutical partners. The company aims to address substantial unmet medical needs in cancer treatment, thereby establishing a broad customer base reliant on its innovative therapeutic solutions.
Sales and Marketing
The company’s marketing and distribution strategies encompass a multi-faceted approach, focusing on direct engagement with healthcare professionals, researchers, and key opinion leaders in the oncology space. The company aims to build comprehensive awareness regarding the potential benefits of its therapeutic pipeline.
Additionally, the company operates in strategic partnerships and collaborations to enhance its marketing efforts, ensuring that its innovative therapies reach the appropriate target markets effectively. By establishing a strong presence within the oncology community, the company seeks to position itself advantageously in terms of therapeutic adoption and market penetration.
Government Regulations
The company is subject to regulations from various health authorities, including the U.S. Food and Drug Administration (FDA) and similar bodies in other jurisdictions.
Compliance with good laboratory practices (GLP), good clinical practices (GCP), and other relevant regulations is essential to ensure the safety and efficacy of the company’s products.
History
The company was incorporated in 1968. It was formerly known as Kitov Pharma Ltd and changed its name to Purple Biotech Ltd. in December 2020.
The Analyst Price Target shows the analysts’ low, high, and average target at a glance.
